Table 1.
Baseline Clinical Characteristics of the 2 Groups
| Controls (n=43) | DCM (n=31) | P value | |
|---|---|---|---|
| Age, y | 62.9±13.6 | 57.2±16.0 | 0.198 |
| Male participants | 32 (74.4) | 25 (80.6) | 0.728 |
| Body mass index, kg/m2 | 25.5±4.0 | 23.6±4.7 | 0.110 |
| New York Heart Association functional class, Ⅰ/Ⅱ/Ⅲ/Ⅳ | … | 0 (0.0)/5 (16.1)/21 (67.7)/5 (16.1) | … |
| Comorbidities | |||
| Hypertension | 23 (53.4) | 18 (58.0) | 0.878 |
| Diabetes | 2 (4.6) | 7 (22.5) | 0.030 |
| Dyslipidemia | 7 (16.2) | 14 (45.1) | 0.014 |
| Atrial fibrillation | 0 (0.0) | 11 (35.4) | <0.001 |
| Laboratory data | |||
| White blood cell, ×103/μL | 5.8±1.3 | 6.8±2.1 | <0.001 |
| Hemoglobin, g/dL | 14.4±1.6 | 14.3±1.5 | 0.671 |
| Platelet, ×103/μL | 218.1±45.4 | 235.4±83.3 | 0.325 |
| Aspartate aminotransferase, U/L | 25.7±12.3 | 28.4±15.4 | 0.400 |
| Alanine transaminase, U/L | 25.6±19.4 | 27.7±23.6 | 0.661 |
| Albumin, g/dL | 4.3±0.3 | 3.8±0.5 | 0.001 |
| Creatinine, mg/dL | 0.8±0.1 | 1.0±0.2 | 0.001 |
| Hemoglobin A1c, % | 5.9±0.4 | 5.7±0.6 | 0.198 |
| Uric acid, mg/dL | 5.3±1.0 | 6.8±2.0 | 0.001 |
| Low‐density lipoprotein cholesterol, mg/dL | 105.3±22.4 | 106.2±22.5 | 0.939 |
| C‐reactive protein, mg/dL | 0.10 (0.06–0.15) | 0.32 (0.08–1.09) | 0.036 |
| B‐type natriuretic peptide, pg/mL | 15.4 (10.8–50.8) | 172.5 (72.0–310.4) | <0.001 |
| Troponin I, ng/mL | … | 0.024 (0.017–0.106) | … |
| Echocardiography | |||
| Left ventricular end‐diastolic dimension, mm | 44.8±5.4 | 61.2±9.5 | <0.001 |
| Left ventricular ejection fraction, % | 65.2±3.9 | 32.3±16.2 | <0.001 |
| Medication | |||
| Renin‐angiotensin system inhibitors | 0 | 27 (87.1) | <0.001 |
| β‐blockers | 0 | 26 (83.9) | <0.001 |
| Diuretics | 0 | 21 (67.7) | <0.001 |
Data are presented as mean±SD, median (interquartile range), or number (percentage). DCM indicates patients with dilated cardiomyopathy.